Company intelligence / Profile preview

Plant Health Care

Ownership: Private
Development stage: Commercial

Overview

Plant Health Care has commercialized several biological products based on recombinant proteins and peptides that act as biostimulants or "vaccines for plants," improving yield and disease resistance. Flagship products include Harpinαß and PHC279. The PREtec platform continues to generate new candidates with at least one new product launch per year planned. Recent launches include Saori® in Brazil (2021), Obrona™ in the US (2023), and Teikko™ peptide nematicide for soybeans launching 2024.

Therapeutic areas: Other
Modalities: Recombinant proteinPeptideBiologic
Industry: Agriculture & AgTech

Drug pipeline

1 asset

Saori

Commercial

Indications: Agricultural crop protection

Partnerships

Wilbur-Ellis (US distribution partner for Obrona™)Nutrien Ag Solutions (Brazilian partner for Saori®)Various specialist distributors worldwide

Beyond the preview

Go deeper on Plant Health Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plant Health Care.

Explore the full profile